Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 11, 2009
Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challengesStephanie R Earnshaw, Michele Wilson, Josephine Mauskopf, et al.
Stroke|September 30, 2006
Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhageStephanie R Earnshaw, Ashish V Joshi, Michele R Wilson, et al.
Health Policy (Amsterdam, Netherlands)|March 18, 2008
Allocating HIV prevention resources: a tool for state and local decision makingAnke Richter, Katherine A Hicks, Stephanie R Earnshaw, et al.
Archives of Internal Medicine|February 18, 2011
Cost-utility of aspirin and proton pump inhibitors for primary preventionStephanie R Earnshaw, James Scheiman, A Mark Fendrick, et al.
Clinical Therapeutics|June 15, 2012
Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United KingdomStephanie R Earnshaw, Cheryl McDade, Ann-Marie Chapman, et al.
Patient Preference and Adherence|March 9, 2012
Spillover adherence effects of fixed-dose combination HIV therapyTeresa L Kauf, Keith L Davis, Stephanie R Earnshaw, et al.
Managed Care Interface|November 4, 2005
A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumoniaStephanie R Earnshaw, Sean D Candrilli, Ancilla W Fernandes, et al.
BMC Infectious Diseases|April 26, 2012
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in CanadaStephanie R Earnshaw, Cheryl L McDade, Giovanni Zanotti, et al.
Applied Health Economics and Health Policy|September 8, 2009
Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosisStephanie R Earnshaw, Jonathan Graham, MerriKay Oleen-Burkey, et al.
Clinical Endocrinology|June 1, 1983
Experience with trilostane in the treatment of Cushing's syndromeP Dewis, D C Anderson, D E Bu'lock, et al.
Pageof 5